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Introduction {#sec005}
============

Identifying glaucoma progression is essential to determine whether treatment should be modified to preserve vision and also to define the endpoints in clinical trials \[[@pone.0235255.ref001]--[@pone.0235255.ref003]\]. The detection of progression is challenging however \[[@pone.0235255.ref003]\], in part because of measurement variability \[[@pone.0235255.ref004]--[@pone.0235255.ref006]\] and in part because structural and functional assessments do not always agree \[[@pone.0235255.ref004], [@pone.0235255.ref007]--[@pone.0235255.ref009]\]. In addition, the lack of a known ground truth for glaucoma progression \[[@pone.0235255.ref010], [@pone.0235255.ref011]\] makes it impossible to evaluate with precision the sensitivities of different clinical tests. As an alternative, previous studies \[[@pone.0235255.ref011]--[@pone.0235255.ref013]\] have used the hit rate or positive rate to evaluate the performance of different tests at a fixed level of specificity, because arguably, a greater positive rate implies a greater sensitivity to detect progression.

Static automated perimetry (SAP) remains the clinical standard \[[@pone.0235255.ref002], [@pone.0235255.ref014]\], yet clinicians also rely on additional tests to monitor glaucoma progression: some based on retinal imaging \[[@pone.0235255.ref002], [@pone.0235255.ref015], [@pone.0235255.ref016]\] and others based on alternative forms of visual function testing \[[@pone.0235255.ref014], [@pone.0235255.ref017], [@pone.0235255.ref018]\]. For monitoring structural change in glaucoma, retinal nerve fiber layer thickness (RNFLT) measured either with scanning laser polarimetry \[[@pone.0235255.ref016]\] or optical coherence tomography (OCT) \[[@pone.0235255.ref019]\] has been shown to be more sensitive than neuro-retinal rim area (RA) obtained with confocal laser scanning ophthalmoscopy (CSLO). Furthermore, OCT has been reported to identify progression earlier than SAP in the early to moderate stages of glaucoma \[[@pone.0235255.ref020], [@pone.0235255.ref021]\]. Frequency doubling technology (FDT) perimetry has also been shown to identify progression earlier than SAP \[[@pone.0235255.ref022], [@pone.0235255.ref023]\]. Some reports, however, suggest that FDT and SAP have similar abilities to detect progression \[[@pone.0235255.ref014], [@pone.0235255.ref018], [@pone.0235255.ref024]\]. Despite the availability of these different tests, there is no agreement in the literature as to which tests are more sensitive to identify progression.

Although structural damage can precede functional loss in glaucoma, randomized clinical trials \[[@pone.0235255.ref007], [@pone.0235255.ref025], [@pone.0235255.ref026]\] and prospective cohort studies \[[@pone.0235255.ref009], [@pone.0235255.ref027], [@pone.0235255.ref028]\] have shown that functional deterioration can be detected in the absence of structural damage. Given that progression can be detected first on either structure or function in different eyes, it may be advantageous to assess both meticulously. Previous studies have investigated different approaches to combine structural and functional parameters with the goal of improving the detection of progression. Medeiros et al. developed a combined structure-function index which provides a percentage estimate of retinal ganglion cell loss \[[@pone.0235255.ref029]\]. Other attempts include statistical models that use structure and function measurements jointly to monitor glaucoma changes \[[@pone.0235255.ref030]\] and use structural information as a prior to estimate functional changes \[[@pone.0235255.ref031], [@pone.0235255.ref032]\]. In spite of these efforts, there is currently no consensus on how to use the information from multiple tests to identify change in glaucoma. The aim of this study was to develop a simple framework to assess glaucoma progression with structural and functional indices jointly.

Methods {#sec006}
=======

Participants {#sec007}
------------

We included 207 patients with ocular hypertension (OHT) or primary open-angle glaucoma (POAG) enrolled in the Diagnostic Innovations in Glaucoma Study (DIGS) or the African Descent and Glaucoma Evaluation Study (ADAGES). The DIGS and ADAGES are longitudinal studies designed to evaluate structure and visual function in healthy, OHT and POAG subjects at multiple study centers \[[@pone.0235255.ref033]\]. The DIGS and ADAGES followed the tenets of the Declaration of Helsinki and obtained the consent of all participants. The Institutional Review Board (IRB) at University of California, San Diego (UCSD) approved the DIGS study. The ADAGES was also approved by the IRBs at the 3 study centers: New York Eye and Ear Infirmary, University of Alabama at Birmingham (UAB) and UCSD. The current study was approved by the IRB at UAB. Eligibility included open anterior chamber angle, best-corrected visual acuity of 20/40 or better, spherical correction \< 5 D and astigmatism \< 3 D, one good-quality stereophotograph and one reliable visual field result. Participants with a history of intraocular surgery (except uncomplicated cataract or glaucoma surgery), secondary glaucoma, other ocular and systemic diseases that affect the visual field, cognitive impairment and inability to perform visual field tests reliably were not eligible. We adopted the classification scheme described in Sample et al \[[@pone.0235255.ref033]\] to classify participants at baseline. Participants with normal optic disc appearance but an intraocular pressure (IOP) ≥ 22 mmHg were classified as OHT patients. With or without elevated IOP, participants with 2 consecutive abnormal optic disc appearances and/or 3 consecutive abnormal visual fields were classified as POAG patients.

Inclusion criteria for the current study {#sec008}
----------------------------------------

The present study included only participants who had 9 visits with OCT and SAP tests. At each visit, we required that OCT and SAP tests be taken no more than 30 days apart (both tests were taken on the same day in 73% of the visits and within a week in 87% of the visits). We also required that consecutive visits be separated by at least 2 months and by no more than 36 months.

Structural assessment {#sec009}
---------------------

RNFLT was measured with the Spectralis spectral domain OCT (software version 5.2.0.3, Heidelberg Engineering, Heidelberg, Germany). The Spectralis SD-OCT combines a dual-beam and CSLO to obtain high resolution RNFL circular scan. Each circular scan consisted of 1536 A-scans along a 3.45-mm circle centered on the optic nerve head \[[@pone.0235255.ref034]\]. Procedurally, pairs of thickness values from neighboring A-scans are averaged, and the resulting 768 RNFLT data points usually summarized as a global RNFLT. Sectorial RNFLT values were computed by averaging the thickness data points in each sector. The Imaging Data Analysis and Evaluation Reading Center at the Department of Ophthalmology, University of California, San Diego, assessed the quality of the OCT scans \[[@pone.0235255.ref033]\]. Only OCT scans with signal strength ≥ 15 dB and no artifacts were included \[[@pone.0235255.ref035]\]. When more than three good quality scans were taken on the same day, we randomly selected three scans and averaged them to obtain RNFLT.

Functional assessment {#sec010}
---------------------

All patients had a 24--2 SAP test at each visit. This was performed using the Swedish Interactive Thresholding Algorithm (SITA Standard) strategy on the Humphrey Field Analyzer II-i (Carl Zeiss Meditec Inc., Dublin, CA). The Visual Field Assessment Center at the Department of Ophthalmology, University of California, San Diego reviewed all visual fields for quality and reliability \[[@pone.0235255.ref036]\]. Only SAP tests with no artifacts and with less than 33% false positives (FP), false negatives (FN) and fixation losses (FL) were included in the present study. Approximately 98% of the 3,677 visual fields used in this study had \< 15% FP and FN values and more than 86% had \< 15% FL. The two locations above and below the blind spot were excluded from the analyses. To obtain the global mean sensitivity (SAP MS) values, the remaining 52 sensitivities were first converted from logarithmic (decibel, dB) into a linear scale, averaged as in Garway-Heath et al \[[@pone.0235255.ref037]\] and then converted back into decibel unit. Averaging the sensitivities in the linear scale minimizes overestimation of depth of defect as explained in Hood et al \[[@pone.0235255.ref038]\]. We also determined SAP MS values for the central region of the visual field by averaging the sensitivities for the 16 test points within the central region as described in Garway-Heath et al \[[@pone.0235255.ref037]\]. Likewise, SAP MS values were obtained for the infero-temporal (IT) and supero-temporal (ST) sectors as defined by the Garway-Heath map \[[@pone.0235255.ref039]\].

Data analysis {#sec011}
-------------

Positive rates and 95% confidence intervals were obtained for the RNFLT and SAP MS individually and jointly. To assess progression with each index alone, we used simple linear regression to estimate the rate of change and computed the *t*-statistic and *p*-value for the one-tailed test that the slope is significantly negative (i.e., there is deterioration over time). This was done for each series length (5 to 9 visits). The specificity of the test was set at 95%, that is, the significance level was set to 0.05.

When progression was assessed using both indices jointly, we applied simple linear regression to each index individually and used two different criteria to determine the joint significance level. For the first criterion, an eye was flagged as progressing if the slopes for both RNFLT and SAP MS were significantly negative. We refer to this approach as the ALL criterion (worsening on both RNFLT and SAP MS). For the second criterion, an eye was flagged as progressing if the slope for either RNFLT or SAP MS was significantly negative. We refer to this approach as the ANY criterion (worsening on either RNFLT or SAP MS). [Fig 1](#pone.0235255.g001){ref-type="fig"} illustrates these two progression criteria for using RNFLT and SAP MS jointly. To ensure a fair comparison between the positive rates for the individual indices and joint analyses, we fixed specificity at 95% by determining the marginal significance level needed for each joint criterion (see [S1 Appendix](#pone.0235255.s001){ref-type="supplementary-material"}). This is needed because using a significance level of 0.05 for the ALL and ANY criteria would result in specificities of 99.75%, and 89.75%, respectively. Thus, the ANY criterion, with its lower specificity, would appear to be more sensitive than the ALL criterion. Eyes were flagged as progressing when the joint p-values were smaller than 0.224 for the ALL criterion and when they were smaller than 0.025 for the ANY criterion.

![Illustration of the ALL and ANY criteria for progression with a structural (RNFLT) and a functional (SAP MS) index based on the one-tailed t-test that the slope is zero versus the slope is negative for simple linear regression.\
The individual null t-distributions are shown in the left (RNFLT) and bottom (SAP MS) panels. The critical region for the ALL criterion is demarcated with the red lines and the critical region for the ANY criterion is demarcated with the blue lines. Any pair of t-values in the area defined by the red lines would be classified as progressing by the ALL criterion. Any pair of t-values in the area defined by the blue lines would be classified as progressing by the ANY criterion. The open circles represent the joined t-values for individual eyes. The solid black circles are the observed t-values for RNFLT and SAP MS slopes derived from a series of 7 visits for an eye flagged as progressing with the ALL criterion for one eye. For clarity of presentation, the t-distribution range was restricted to t-values within-- 4 to 4, which resulted in the exclusion of 80 eyes.](pone.0235255.g001){#pone.0235255.g001}

[Table 1](#pone.0235255.t001){ref-type="table"} shows the marginal significance levels needed at three different levels of specificity, including the level used in this study (95%). Details on how to obtain marginal significance levels to fix specificity at any level for any number of functional and structural tests, and different progression criteria are given in the [S1 Appendix](#pone.0235255.s001){ref-type="supplementary-material"}. The level of agreement between individual indices and the joint assessment criteria was determined using the Kappa statistic (қ) \[[@pone.0235255.ref040]\]. With this statistic, agreement can be slight (0--0.20), fair (0.21--0.40), moderate(0.41--0.60), substantial (0.61--0.80), or almost perfect (0.81--1). The time-to-detection of progression was also compared between the individual and the joint progression criteria using Kaplan-Meier analysis \[[@pone.0235255.ref041]\]. All analyses were performed using R \[[@pone.0235255.ref042]\].

10.1371/journal.pone.0235255.t001

###### Marginal significance levels for different progression criteria.

![](pone.0235255.t001){#pone.0235255.t001g}

  Progression criterion                               Marginal Significance at different levels of specificity           
  --------------------------------------------------- ---------------------------------------------------------- ------- -------
  Individual index (e.g. RNFLT-alone, SAP MS-alone)   0.100                                                      0.050   0.010
  **ALL**: 2 indices (e.g., RNFLT *and* SAP MS)       0.316                                                      0.224   0.100
  **ANY**: 2 indices (e.g., RNFLT *or* SAP MS)        0.051                                                      0.025   0.005

The marginal significance levels are shown for individual indices and pairs of indices at a set specificity of 90%, 95%, and 99%. (Note: In this study, we set specificity at 95%).

Results {#sec012}
=======

Participants demographic and disease characteristics are presented in [Table 2](#pone.0235255.t002){ref-type="table"}. From the 207 patients, 337 eligible eyes (56 with OHT and 281 with POAG) were included in the analysis. The mean age and mean follow-up of this cohort were 64.3 ± 10.4 years and 4.4 ± 0.87 years, respectively.

10.1371/journal.pone.0235255.t002

###### Demographic and disease characteristics of study participants.

![](pone.0235255.t002){#pone.0235255.t002g}

  Characteristics                                                                              
  ------------------------------------------------------------------------ ------------------- -------------
  Mean age ± SD (years)                                                    64.3 ± 10.4         
  Mean follow up time ± SD (years)                                         4.4 ± 0.87          
  Gender (N = 207)                                                         *Female*            117 (56.5%)
  *Male*                                                                   90 (43.5%)          
  Race (N = 207)                                                           *African descent*   90 (43.5%)
  *European descent*                                                       102 (49.3%)         
  *Others*                                                                 15 (7.2%)           
  Disease classification (N = 337 eyes)                                    *OHT*               56 (16.6%)
  *POAG*                                                                   281 (83.4%)         
  Disease severity (POAG eyes only)[\*](#t002fn002){ref-type="table-fn"}   *Mild*              226 (80.4%)
  *Moderate*                                                               33 (11.7%)          
  *Advanced*                                                               22 (7.8%)           

SD = standard deviation

\*Severity classification based on Hoddapp-Parrish-Anderson criteria \[[@pone.0235255.ref043]\].

[Fig 2](#pone.0235255.g002){ref-type="fig"} shows the positive rates obtained globally and in three sectors for RFNLT-alone, SAP MS-alone and for the different criteria used to assess progression with these 2 indices jointly. Positive rates for individual indices and for the joint analyses generally increased with series length as expected. For the individual indices, the positive rates for RNFLT-alone (10% to 45%) were higher than those observed for SAP MS-alone (5% to 23%). When RNFLT and SAP MS were analyzed jointly, the ANY criterion (worsening on either RNFLT or SAP MS) had higher positive rates (9% to 46%) compared to the ALL criterion (6% to 27%), with on average 10.6% more eyes flagged as progressing. The positive rates obtained for the ANY criteria were similar to those obtained for RNFLT-alone. Overall, the pattern of results was similar for the global and regional analyses.

![Positive rates and 95% confidence intervals for RNFLT-alone (solid circles), SAP MS-alone (empty circles), the ALL criteria (empty triangles) and the ANY criteria (solid triangles) for series of 5 to 9 visits.\
The data are presented for global, infero-temporal (IT), supero-temporal (ST), and Central region from the left to the right panels.](pone.0235255.g002){#pone.0235255.g002}

Although the joint assessments using the ANY criterion did not significantly improve the detection of progression compared to RNFLT-alone, different subset of eyes were identified as progressing. The proportional Venn diagrams shown in [Fig 3](#pone.0235255.g003){ref-type="fig"} illustrate the agreement between the eyes identified as progressing with RNFLT-alone and the ANY criterion. There was moderate to substantial agreement between RNFLT-alone and the ANY criterion, with kappa values ranging 0.55 to 0.75. Depending on the number of visits and sector assessed, 13 to 27 eyes were uniquely identified as progressing with RNFLT-alone, whereas 9 to 38 eyes were uniquely identified by the ANY criterion. A similar analysis showed no agreement to slight agreement between SAP MS alone and RNFLT alone (қ = -0.07 to 0.04), with 13 to 47 eyes uniquely identified by SAP MS alone.

![Proportional Venn diagrams illustrating the agreement between the eyes identified as progressing by RNFLT-alone and by the ANY criterion (RNFLT or SAP MS) for visits 5, 7 and 9.\
The Kappa statistic is shown at the bottom of each panel.](pone.0235255.g003){#pone.0235255.g003}

In addition to the positive rates, we were interested in assessing the time-to-detection of each joint criterion compared to each index alone. The results of the Kaplan-Meier analysis are shown in [Fig 4](#pone.0235255.g004){ref-type="fig"}. The median time-to-detection (time taken to detect 50% of the eyes as progressing) for both RNFLT-alone and the ANY (RNFLT or SAP MS) criterion was approximately 32 months. For this same period of time, SAP MS detected less than 25% of the eyes as progressing.

![Estimated Kaplan-Meier survival curves for RNFLT and SAP MS as well as for the ALL and ANY criteria.](pone.0235255.g004){#pone.0235255.g004}

Discussion {#sec013}
==========

The framework developed in this study provides a formalized approach to evaluate the results of longitudinal structural and functional data jointly. The ALL and ANY progression criteria are similar in principle to the fundamental "all positive" and "either positive" rules that are commonly applied to analyze results from two clinical tests jointly \[[@pone.0235255.ref044]\]. To guard against increases in sensitivity that result from decreases in specificity when multiple tests are used jointly, we fixed specificity at 95% by determining the marginal significance level for each progression criterion. [Fig 5](#pone.0235255.g005){ref-type="fig"} presents progression outcomes determined for four different patients to illustrate the different joint progression criteria. Panel A shows longitudinal data for a glaucoma patient who is not progressing. The individual slopes for RNFLT and MS are not significant and when considered jointly, the t-values do not reach statistical significance for the ANY and ALL criteria. In panel B, the individual longitudinal data from RNFLT and SAP MS disagree, with a significant slope for MS-alone and a non-significant slope for RNFLT. When considering both tests jointly, the t-value associated with the SAP MS p-value is large enough to exceed the cut-off value of the ANY criterion (see [Table 1](#pone.0235255.t001){ref-type="table"}). A determination of progression can therefore be made for this patient. The example presented in panel C is similar, but with enough change observed for RNFLT. While the data for the patient presented in panel D shows only slight, non-significant, worsening on SAP MS and RNFLT individually, because there is worsening on both tests, progression is detected based on the ALL criteria when a joint assessment is performed.

![The SAP MS and RNFLT data are presented for four patients, along with the joint structural and functional assessment.\
When the slopes for both SAP MS and RNFLT are not statistically significant individually, the joint assessment can yield different outcomes depending on the direction and magnitude of the individual slopes. For example, the joint assessment of the patient in Panel A does not show progression, but that of the patient shown in Panel D shows progression. When there is disagreement between the longitudinal assessments of RNFLT and SAP MS, the ANY criteria will flag an eye as significant when a stricter marginal significance cut-off is reached for one of the measurements.](pone.0235255.g005){#pone.0235255.g005}

The proposed framework requires marginal significance levels to be determined for the joint analysis of two (see [Table 1](#pone.0235255.t001){ref-type="table"}) or more indices ([S1 Appendix](#pone.0235255.s001){ref-type="supplementary-material"}). This allows for as many parameters as desired to be considered jointly at a given level of specificity. The [S1 Appendix](#pone.0235255.s001){ref-type="supplementary-material"} explains how it is possible to group indices in different combinations (AND and OR) before applying the ANY and ALL criteria. For instance, information from 24--2 and 10--2 SAP tests can be analyzed jointly with peripapillary RNFLT and macula data from OCT. As new tests and parameters emerge in the future, this approach can be used to determine the optimal combination to identify glaucoma progression.

As mentioned in the Introduction, progression in different patients, can be detected first with either structural or functional measurements \[[@pone.0235255.ref026]--[@pone.0235255.ref028], [@pone.0235255.ref045]\]. The notion that using both types of measurements jointly may therefore improve the detection of glaucoma progression has led to the development of several strategies for joint structure-function analysis. The approach we propose in this study is similar to the Bayesian joint regression model developed by Medeiros et al \[[@pone.0235255.ref032]\], in that the identification of progression is based on the joint assessment of longitudinal structural and functional data. While the accuracy and precision of the slopes were assessed in that Bayesian model, its sensitivity was not evaluated. The framework we have proposed in this study can be used to perform such evaluations. Moreover, the framework is not limited to a specific definition of glaucoma progression. Besides the trend-based approach used in our study, other statistical methods of assessing progression, such as event-based \[[@pone.0235255.ref003]\] and permutation analyses \[[@pone.0235255.ref013]\], can be applied within this framework. For example, the outcomes of guided progression analysis from both OCT and SAP can be interpreted jointly with this framework at a desired level of specificity. A "possible progression" outcome on both devices may be considered a stronger indication of progression compared to a "likely progression" outcome from a single test.

Another model developed to assess progression using structural and functional data jointly is a complex multivariate mixed-effects model \[[@pone.0235255.ref046]\]. It was implemented within a Bayesian hierarchical modeling framework and identified progression in a significantly higher proportion of eyes (approximately 10% more eyes) compared to simple linear regression. In contrast, our results show that combining structure and function does not improve the detection of progression over using structure alone. This observation may have resulted from the application of a fixed specificity level, which ensured that the assessment of progression with RNFLT, alone or in combination with SAP MS, was held to the same level of statistical significance. Yousefi et al \[[@pone.0235255.ref047]\] applied various machine learning classifiers to structural and functional data individually and in combination. Similar to our findings, they reported that RNFLT-alone performs as well as the combination of RNFLT and SAP MS. Finally, in support of our finding that the joint analysis did not have a significant advantage over using structure alone, we observed that RNFLT alone and its combination with SAP MS had similar time-to-detection of progression ([Fig 4](#pone.0235255.g004){ref-type="fig"}).

Several studies \[[@pone.0235255.ref018], [@pone.0235255.ref048]--[@pone.0235255.ref050]\] have reported poor agreement between eyes identified as progressing by OCT and SAP indices. In the current study, the positive rates obtained for RNFLT-alone and the ANY criterion were approximately the same, however, different eyes were identified as progressing by each criterion ([Fig 3](#pone.0235255.g003){ref-type="fig"}). This is due to the detection of progression at different levels of significance between RNFLT-alone and the ANY criterion. As such, an eye that is identified as progressing by RNFLT-alone may not necessarily have the same outcome with the ANY criterion and vice versa. This finding suggests that when combining information from different tests to assess progression, it is also important to carefully consider the results of each test independently.

In clinical practice, SAP continues to be used as the preferred standard test for monitoring progression in moderate and advanced disease. The preference of SAP over OCT is often explained by the presence of a floor effect in RNFLT measurement with OCT \[[@pone.0235255.ref038], [@pone.0235255.ref051]\], a range beyond which no useful change in thickness can be detected. Recent studies, however, showed that whereas OCT was more sensitive for detecting progression in early glaucoma, its performance may not be significantly worse than SAP in moderate and advanced glaucoma eyes \[[@pone.0235255.ref020], [@pone.0235255.ref021]\]. Medeiros et al, however, showed that a single index generated by weighting structure and function based on disease severity was better at discriminating different disease stages \[[@pone.0235255.ref029]\]. This suggests that using structural and functional tests together to identify progression may perform differently across the spectrum of glaucoma severity. We compared positive rates between SAP MS, RNFLT and the ANY criterion in different glaucoma severities for the POAG eyes. The results from this analysis, presented in [Table 3](#pone.0235255.t003){ref-type="table"}, show that using SAP MS alone or in combination with RNFLT may not perform better than using RNFLT alone in advanced disease. This implies that even in advanced disease, SAP may perform similarly to OCT to detect change. Comparable to the floor effect in RNFLT measurement with OCT, studies have shown that the ability of SAP to detect progression is limited when perimetric threshold estimates falls below 15--20 dB \[[@pone.0235255.ref052], [@pone.0235255.ref053]\]. Our analysis and that of previous studies \[[@pone.0235255.ref020], [@pone.0235255.ref021]\] involved a smaller sample of eyes with advanced disease. Further studies with larger samples of advanced glaucoma eyes are therefore needed to properly address whether SAP and OCT have different sensitivities in advanced disease.

10.1371/journal.pone.0235255.t003

###### Positive rates and Kappa (k) agreement between RNFLT and ANY criterion in different severity of disease.

![](pone.0235255.t003){#pone.0235255.t003g}

  Visits   Mild (N = 226)   Moderate (N = 33)   Advanced (N = 22)                                                                 
  -------- ---------------- ------------------- ------------------- ------ ------- ------- ------- ------ ------- ------- ------- ------
  **5**    7.10             30.50               23.50               0.73   9.09    24.24   18.18   0.46   13.64   9.09    9.09    0.45
  **7**    14.60            39.40               38.90               0.71   18.18   36.36   30.30   0.73   9.09    9.09    13.64   0.78
  **9**    24.80            44.70               48.20               0.68   18.18   42.42   42.42   0.63   18.18   27.27   18.18   0.49

The results reported herein should be considered in light of some limitations. First, our definition of progression was not adjusted for change due to normal aging. We did not correct for aging because, unlike mean deviation from SAP test, a conventional model to discount for age effects in RNFLT measurement is lacking. Moreover, the main focus of this study was to provide a framework to compare the detection of change by different test parameters, alone or in combination. Proposed strategies to adjust for aging, such as using the mean normal rate of change or the 5% lower limit as a reference \[[@pone.0235255.ref054]\], can be applied in our framework in future studies. The second limitation, a challenge for most progression detection methods, was the inability of all criteria to consistently identify the same eyes as progressing over time. We maintained a false positive rate of 5% for each progression criterion and across all series length, however, the between visit agreement presented in [Table 4](#pone.0235255.t004){ref-type="table"} shows that some eyes flagged as progressing at a particular visit were not flagged as such at subsequent visits, irrespective of the progression criterion applied. Because of the lack of a reference standard for glaucoma progression, some eyes may be identified as progressing when they are not (type I error), and other eyes may not be identified as progressing when in fact change is occurring (type II error). In addition, the variability present in the short follow-up data may account for the misidentification of eyes.

10.1371/journal.pone.0235255.t004

###### Between-visit agreement (kappa) for eyes flagged as progressing by SAP MS-alone, RNFLT-alone, and the ANY criterion.

![](pone.0235255.t004){#pone.0235255.t004g}

                      SAP MS-alone   RNFLT-alone   ANY
  ------------------- -------------- ------------- ------
  **Visit 5 and 6**   0.45           0.69          0.63
  **Visit 6 and 7**   0.71           0.74          0.69
  **Visit 7 and 8**   0.69           0.79          0.73
  **Visit 8 and 9**   0.66           0.76          0.81

In conclusion, several tests and parameters are currently available to monitor glaucoma progression. Each of these, as well as others that will be identified in the future, offer unique insights into glaucoma progression. The framework described in this study allows for many parameters to be considered jointly at fixed specificity levels. It is also compatible with different statistical methods to assess glaucoma progression. The framework allows the integration of different perspectives when monitoring glaucoma patients, allowing clinicians to jointly consider change on several clinically useful indices.
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###### Derivation of marginal significance levels to fix specificity at any level for the joint analysis.

(PDF)

###### 

Click here for additional data file.

###### Dataset for 337 eyes containing only RNFLT and SAP MS measurements.

(CSV)

###### 

Click here for additional data file.

We thank the principal investigators of the DIGS and ADAGES studies for granting us permission to use these data for this study. We are also grateful to the staff of the Visual Field Assessment Center and the Imaging Data Analysis and Evaluation Reading Center at the Department of Ophthalmology, University of California, San Diego, who assessed and ensured data quality.

[^1]: **Competing Interests:**Co-author \[IMF\] is the founder of Computational Optometry from which he freelances for various vision scientists. Computational Optometry did not provide support in the form of salaries and did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. IMF's affiliation with Computational Optometry does not alter our adherence to PLOS ONE policies on sharing data and materials.
